Evaluation of the SPF10-INNO LiPA Human Papillomavirus (HPV) Genotyping Test and the Roche Linear Array HPV Genotyping Test

Overview

Journal J Clin Microbiol

Specialty Microbiology

Date 2006 Sep 7

PMID 16954236

Citations 61

Authors

Dennis van Hamont

Maaike A P C van Ham

Judith M J E Bakkers

Leon F A G Massuger

Willem J G Melchers

Affiliations

Soon will be listed here.

Abstract

The need for accurate genotyping of human papillomavirus (HPV) infections is becoming increasingly important, since (i) the oncogenic potential among the high-risk HPV genotypes varies in the pathogenesis of cervical cancer, (ii) monitoring multivalent HPV vaccines is essential to investigate the efficiency of the vaccines, and (iii) genotyping is crucial in epidemiologic studies evaluating HPV infections worldwide. Various genotyping assays have been developed to meet this demand. Comparison of different studies that use various HPV genotyping tests is possible only after a performance assessment of the different assays. In the present study, the SPF(10) LiPA version 1 and the recently launched Roche Linear Array HPV genotyping assays are compared. A total of 573 liquid-based cytology samples were tested for the presence of HPV by a DNA enzyme immunoassay; 210 were found to be positive for HPV DNA and were evaluated using both genotyping assays (163 with normal cytology, 22 with atypical squamous cells of undetermined significance, 20 with mild/moderate dysplasia, and 5 with severe dysplasia). Comparison analysis was limited to the HPV genotype probes common to both assays. Of the 160 samples used for comparison analysis, 129 (80.6%) showed absolute agreement between the assays (concordant), 18 (11.2%) showed correspondence for some but not all genotypes detected on both strips (compatible), and the remaining 13 (8.2%) samples did not show any similarity between the tests (discordant). The overall intertest comparison agreement for all individually detectable genotypes was considered very good (kappa value, 0.79). The genotyping assays were therefore highly comparable and reproducible.

Citing Articles

Human Papilloma Virus Infection in Men: A Specific Human Virome or a Specific Pathology?.

culav I, Skerlev M, Starcevic L, Hrabac P, Ljubojevic Hadzavdic S, Beslic I Genes (Basel). 2025; 16(2).

PMID: 40004559 PMC: 11855728. DOI: 10.3390/genes16020230.

Head-to-head comparison of 7 high-sensitive human papillomavirus nucleic acid detection technologies with the SPF10 LiPA-25 system.

Yin J, Cheng S, Liu D, Tian Y, Hu F, Zhang Z J Natl Cancer Cent. 2024; 2(3):148-154.

PMID: 39036447 PMC: 11256530. DOI: 10.1016/j.jncc.2022.06.003.

Association Between Cervical Inflammatory Mediators and Prevalent Cervical Human Papillomavirus Infection.

Olukomogbon T, Akpobome B, Omole A, Adebamowo C, Adebamowo S JCO Glob Oncol. 2024; 10:e2300380.

PMID: 38547441 PMC: 10994421. DOI: 10.1200/GO.23.00380.

Discrimination of human papillomavirus genotypes using innovative technique nested-high resolution melting.

Alirezaei M, Mosawi S, Afgar A, Zarean M, Movahhed T, Abbasi V Sci Rep. 2022; 12(1):13943.

PMID: 35977949 PMC: 9382607. DOI: 10.1038/s41598-022-14730-9.

Detection of Five Types of HPV Genotypes Causing Anogenital Warts (Condyloma Acuminatum) Using PCR-Tm Analysis Technology.

Wu L, Wang W, Zhang J, Wu X, Chen Y, Gu X Front Microbiol. 2022; 13:857410.

PMID: 35655998 PMC: 9152731. DOI: 10.3389/fmicb.2022.857410.

References

Remmink A, Walboomers J, Helmerhorst T, Voorhorst F, Rozendaal L, Risse E . The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer. 1995; 61(3):306-11. DOI: 10.1002/ijc.2910610305. View

Sherman M, Schiffman M, Lorincz A, Herrero R, Hutchinson M, Bratti C . Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing. Cancer. 1997; 81(2):89-97. View

Cuzick J, Terry G, Ho L, Hollingworth T, Anderson M . Type-specific human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia. Br J Cancer. 1994; 69(1):167-71. PMC: 1968760. DOI: 10.1038/bjc.1994.28. View

Lee K, Ashfaq R, Birdsong G, Corkill M, McIntosh K, Inhorn S . Comparison of conventional Papanicolaou smears and a fluid-based, thin-layer system for cervical cancer screening. Obstet Gynecol. 1997; 90(2):278-84. DOI: 10.1016/S0029-7844(97)00228-7. View

Kleter B, van Doorn L, Ter Schegget J, Schrauwen L, van Krimpen K, Burger M . Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol. 1998; 153(6):1731-9. PMC: 1866345. DOI: 10.1016/S0002-9440(10)65688-X. View

Kleter B, van Doorn L, Schrauwen L, Molijn A, Sastrowijoto S, Ter Schegget J . Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol. 1999; 37(8):2508-17. PMC: 85270. DOI: 10.1128/JCM.37.8.2508-2517.1999. View

Walboomers J, Jacobs M, Manos M, Bosch F, Kummer J, Shah K . Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189(1):12-9. DOI: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F. View

Harper D, Franco E, Wheeler C, Ferris D, Jenkins D, Schuind A . Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004; 364(9447):1757-65. DOI: 10.1016/S0140-6736(04)17398-4. View

Schiffman M, Khan M, Solomon D, Herrero R, Wacholder S, Hildesheim A . A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst. 2005; 97(2):147-50. DOI: 10.1093/jnci/dji014. View

10.

Baseman J, Koutsky L . The epidemiology of human papillomavirus infections. J Clin Virol. 2005; 32 Suppl 1:S16-24. DOI: 10.1016/j.jcv.2004.12.008. View

11.

Steenbergen R, de Wilde J, Wilting S, Brink A, Snijders P, Meijer C . HPV-mediated transformation of the anogenital tract. J Clin Virol. 2005; 32 Suppl 1:S25-33. DOI: 10.1016/j.jcv.2004.11.019. View

12.

Molijn A, Kleter B, Quint W, van Doorn L . Molecular diagnosis of human papillomavirus (HPV) infections. J Clin Virol. 2005; 32 Suppl 1:S43-51. DOI: 10.1016/j.jcv.2004.12.004. View

13.

van Ham M, Bakkers J, Harbers G, Quint W, Massuger L, Melchers W . comparison of two commercial assays for detection of human papillomavirus (HPV) in cervical scrape specimens: validation of the Roche AMPLICOR HPV test as a means to screen for HPV genotypes associated with a higher risk of cervical disorders. J Clin Microbiol. 2005; 43(6):2662-7. PMC: 1151918. DOI: 10.1128/JCM.43.6.2662-2667.2005. View

14.

Castle P, Solomon D, Schiffman M, Wheeler C . Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst. 2005; 97(14):1066-71. DOI: 10.1093/jnci/dji186. View

15.

Bleeker M, Hogewoning C, Berkhof J, Voorhorst F, Hesselink A, van Diemen P . Concordance of specific human papillomavirus types in sex partners is more prevalent than would be expected by chance and is associated with increased viral loads. Clin Infect Dis. 2005; 41(5):612-20. DOI: 10.1086/431978. View

16.

Mahdavi A, Monk B . Vaccines against human papillomavirus and cervical cancer: promises and challenges. Oncologist. 2005; 10(7):528-38. DOI: 10.1634/theoncologist.10-7-528. View

17.

Cuschieri K, Cubie H, Whitley M, Gilkison G, Arends M, Graham C . Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study. J Clin Pathol. 2005; 58(9):946-50. PMC: 1770812. DOI: 10.1136/jcp.2004.022863. View

18.

Clifford G, Gallus S, Herrero R, Munoz N, Snijders P, Vaccarella S . Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005; 366(9490):991-8. DOI: 10.1016/S0140-6736(05)67069-9. View

19.

Melchers W, Bakkers J, Wang J, de Wilde P, Boonstra H, Quint W . Short fragment polymerase chain reaction reverse hybridization line probe assay to detect and genotype a broad spectrum of human papillomavirus types. Clinical evaluation and follow-up. Am J Pathol. 1999; 155(5):1473-8. PMC: 1866998. DOI: 10.1016/S0002-9440(10)65462-4. View

20.

Wallin K, Wiklund F, Angstrom T, BERGMAN F, Stendahl U, Wadell G . Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med. 1999; 341(22):1633-8. DOI: 10.1056/NEJM199911253412201. View